



1. General Information

Cohort ID	5003_20
Title (Study Name)	COVID-19 Convalescent Cohort
Principal investigator	Prof. Robert Krause
Contact information	pm-biobank@medunigraz.at
Funding agency	 

2. Description

<p>This longitudinal cohort comprise a collection of samples from 364 convalescents who were infected with SARS-CoV-2.</p> <ul style="list-style-type: none"> • Sub cohort I: persons who were officially tested positive for SARS-CoV-2 by RT-PCR between 29th of February 2020 and 15th of January 2021, showed symptoms of COVID-19 and have recovered. (342 participants) • Sub cohort II: persons recovered from suspected COVID-19 infection (but COVID-19 infection has not been confirmed by RT-PCR) (22 participants) <p>Study design: Participants are invited 5 times: 1.visit and 4 follow-up visits are performed 1, 2, 5 and 12 months after the first visit where the samples are collected. During the first visit, participants filled in a questionnaire concerning symptoms, comorbidities, prehistory and lifestyle.</p> <p>This cohort serves for e.g.:</p> <ul style="list-style-type: none"> • the development and validation of new antibody tests and neutralization assays • the investigation of antibody titres over time • a better characterization of the course of COVID-19 • the identification of diagnostic or prognostic biomarkers

3. Details

ICD 10/O codes / Healthy	Healthy	
Key words	COVID-19 recovered patients, SARS-Cov-2, PCR test, antibody test, longitudinal cohort	
Collection / Cohort size 11/2021	34.317 aliquots from 366 participants (5 visits)	
Informed Consent (IC)	<input checked="" type="checkbox"/> Broad Biobank IC	
	<input checked="" type="checkbox"/> Specific Study IC	
Status	<input checked="" type="checkbox"/> In progress / compl. date: 03/2022	
	<input type="checkbox"/> Completed	
Inclusion criteria	Age distribution	18-81 years
	Sex distribution (f:m)	61:39
	Others	Patients who have recovered from COVID-19
Earliest access	As of now	

Quality-standards	<input checked="" type="checkbox"/> ISO 9001:2015 (SOPs)
Associated publications / references	<p><u>Long-lasting immune response to a mild course of PCR-confirmed SARS-CoV-2 infection: A cohort study</u> Kral S, Banfi C, Niedrist T, Sareban N, Guelly C, Kriegl L, Schiffmann S, Zurl C, Herrmann M, Steinmetz I, Schlenke P, Berghold A, Krause R. https://pubmed.ncbi.nlm.nih.gov/34433071/</p> <p><u>Longitudinal comparison of automated SARS-CoV-2 serology assays in assessing virus neutralization capacity in COVID-19 convalescent sera</u> Niedrist T, Drexler C, Torreiter PP, Matejka J, Strahlhofer-Augsten M, Kral S, Riegler S, Güllly C, Zurl C, Kriegl L, Krause R, Berghold A, Steinmetz I, Schlenke P, Herrmann M. https://pubmed.ncbi.nlm.nih.gov/35085385/</p> <p><u>Lower Levels of ABO Anti-A and Anti-B of IgM, IgG and IgA Isotypes in the Serum but Not the Saliva of COVID-19 Convalescents.</u> Matzhold EM, Körmöczi GF, Banfi C, Schönbacher M, Drexler-Helmsberg C, Steinmetz I, Berghold A, Schlenke P, Wagner GE, Stoisser A, Kleinhappel B, Mayr WR, Wagner T https://pubmed.ncbi.nlm.nih.gov/35956128/</p>

4. Material available (aliquot size) and storage conditions

Material	<input checked="" type="checkbox"/> Serum (235 µl)	<input checked="" type="checkbox"/> -80°C
	<input checked="" type="checkbox"/> EDTA plasma (300 µl)	<input checked="" type="checkbox"/> -80°C
	<input checked="" type="checkbox"/> EDTA Buffy coat (580 µl)	<input checked="" type="checkbox"/> -80°C
	<input checked="" type="checkbox"/> Li-Hep plasma (235 µl)	<input checked="" type="checkbox"/> -80°C
	<input checked="" type="checkbox"/> Na-Citrate plasma (235 µl)	<input checked="" type="checkbox"/> -80°C
	<input checked="" type="checkbox"/> Saliva	<input checked="" type="checkbox"/> -80°C
	<input checked="" type="checkbox"/> Nasopharyngeal swab	<input checked="" type="checkbox"/> -80°C

Dokument erstellt (tt/mm/yyyy): 11/03/2021	Letzte inhaltliche Aktualisierung (tt/mm/yyyy): 17/08/2022
--	--